Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: A population-based study

Ido Wolf, Noa Ben-Baruch, Ronnie Shapira-Frommer, Shulamit Rizel, Hadassa Goldberg, Neora Yaal-Hahoshen, Baruch Klein, David B. Geffen, Bella Kaufman

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

BACKGROUND. The 21-gene recurrence score (RS) assay has been reported to accurately predict the risk of disease recurrence and chemotherapy benefit in women with estrogen receptor (ER)-positive, lymph node (LN)-negative breast cancer who are treated with tamoxifen. To the authors' knowledge, the association between the RS and clinicopathologic characteristics has been studied in randomized and case-control trials, but not in the general population. METHODS. The authors analyzed the correlation between clinicopathologic breast cancer characteristics and RS among 300 consecutive Israeli patients who were referred to undergo the test between October 2004 and October 2006. RESULTS. Low, intermediate, and high RS were noted in 109 patients (36%), 134 patients (45%), and 57 patients (19%), respectively. The median age of the patients was 54 years and the median tumor size was 1.6 cm. High tumor grade, low progesterone receptor expression, infiltrating ductal histology, and high HER-2 expression were found to be associated with a high RS, whereas patient age, tumor size, ER expression, and lymph node micrometastasis were found to correlate poorly with the RS. The ability of any of these variables, either alone or in combination, to predict the RS was limited. Similarly, neither commonly used guidelines nor the Adjuvant! Online software were found to be able to predict the RS. CONCLUSIONS. The results of the current study suggest that neither standard clinicopathologic features nor commonly used assessment tools can reliably predict the RS among referred breast cancer patients compared with a clinical trial population. These data also may indicate the need for additional studies regarding the role of the RS among certain subsets of breast cancer patients, including those with noninfiltrating ductal carcinoma histology and the presence of lymph node micrometastasis.

Original languageEnglish (US)
Pages (from-to)731-736
Number of pages6
JournalCancer
Volume112
Issue number4
DOIs
StatePublished - Feb 15 2008

Fingerprint

Breast Neoplasms
Recurrence
Population
Genes
Neoplasm Micrometastasis
Lymph Nodes
Estrogen Receptors
Histology
Neoplasms
Ductal Carcinoma
Progesterone Receptors
Tamoxifen
Software
Clinical Trials
Guidelines
Drug Therapy

Keywords

  • Breast cancer
  • Estrogen receptor
  • Grade
  • Progesterone receptor
  • Recurrence score

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients : A population-based study. / Wolf, Ido; Ben-Baruch, Noa; Shapira-Frommer, Ronnie; Rizel, Shulamit; Goldberg, Hadassa; Yaal-Hahoshen, Neora; Klein, Baruch; Geffen, David B.; Kaufman, Bella.

In: Cancer, Vol. 112, No. 4, 15.02.2008, p. 731-736.

Research output: Contribution to journalArticle

Wolf, I, Ben-Baruch, N, Shapira-Frommer, R, Rizel, S, Goldberg, H, Yaal-Hahoshen, N, Klein, B, Geffen, DB & Kaufman, B 2008, 'Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: A population-based study', Cancer, vol. 112, no. 4, pp. 731-736. https://doi.org/10.1002/cncr.23225
Wolf, Ido ; Ben-Baruch, Noa ; Shapira-Frommer, Ronnie ; Rizel, Shulamit ; Goldberg, Hadassa ; Yaal-Hahoshen, Neora ; Klein, Baruch ; Geffen, David B. ; Kaufman, Bella. / Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients : A population-based study. In: Cancer. 2008 ; Vol. 112, No. 4. pp. 731-736.
@article{ecdea186ddb74b49b5c3112679c27de5,
title = "Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: A population-based study",
abstract = "BACKGROUND. The 21-gene recurrence score (RS) assay has been reported to accurately predict the risk of disease recurrence and chemotherapy benefit in women with estrogen receptor (ER)-positive, lymph node (LN)-negative breast cancer who are treated with tamoxifen. To the authors' knowledge, the association between the RS and clinicopathologic characteristics has been studied in randomized and case-control trials, but not in the general population. METHODS. The authors analyzed the correlation between clinicopathologic breast cancer characteristics and RS among 300 consecutive Israeli patients who were referred to undergo the test between October 2004 and October 2006. RESULTS. Low, intermediate, and high RS were noted in 109 patients (36{\%}), 134 patients (45{\%}), and 57 patients (19{\%}), respectively. The median age of the patients was 54 years and the median tumor size was 1.6 cm. High tumor grade, low progesterone receptor expression, infiltrating ductal histology, and high HER-2 expression were found to be associated with a high RS, whereas patient age, tumor size, ER expression, and lymph node micrometastasis were found to correlate poorly with the RS. The ability of any of these variables, either alone or in combination, to predict the RS was limited. Similarly, neither commonly used guidelines nor the Adjuvant! Online software were found to be able to predict the RS. CONCLUSIONS. The results of the current study suggest that neither standard clinicopathologic features nor commonly used assessment tools can reliably predict the RS among referred breast cancer patients compared with a clinical trial population. These data also may indicate the need for additional studies regarding the role of the RS among certain subsets of breast cancer patients, including those with noninfiltrating ductal carcinoma histology and the presence of lymph node micrometastasis.",
keywords = "Breast cancer, Estrogen receptor, Grade, Progesterone receptor, Recurrence score",
author = "Ido Wolf and Noa Ben-Baruch and Ronnie Shapira-Frommer and Shulamit Rizel and Hadassa Goldberg and Neora Yaal-Hahoshen and Baruch Klein and Geffen, {David B.} and Bella Kaufman",
year = "2008",
month = "2",
day = "15",
doi = "10.1002/cncr.23225",
language = "English (US)",
volume = "112",
pages = "731--736",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients

T2 - A population-based study

AU - Wolf, Ido

AU - Ben-Baruch, Noa

AU - Shapira-Frommer, Ronnie

AU - Rizel, Shulamit

AU - Goldberg, Hadassa

AU - Yaal-Hahoshen, Neora

AU - Klein, Baruch

AU - Geffen, David B.

AU - Kaufman, Bella

PY - 2008/2/15

Y1 - 2008/2/15

N2 - BACKGROUND. The 21-gene recurrence score (RS) assay has been reported to accurately predict the risk of disease recurrence and chemotherapy benefit in women with estrogen receptor (ER)-positive, lymph node (LN)-negative breast cancer who are treated with tamoxifen. To the authors' knowledge, the association between the RS and clinicopathologic characteristics has been studied in randomized and case-control trials, but not in the general population. METHODS. The authors analyzed the correlation between clinicopathologic breast cancer characteristics and RS among 300 consecutive Israeli patients who were referred to undergo the test between October 2004 and October 2006. RESULTS. Low, intermediate, and high RS were noted in 109 patients (36%), 134 patients (45%), and 57 patients (19%), respectively. The median age of the patients was 54 years and the median tumor size was 1.6 cm. High tumor grade, low progesterone receptor expression, infiltrating ductal histology, and high HER-2 expression were found to be associated with a high RS, whereas patient age, tumor size, ER expression, and lymph node micrometastasis were found to correlate poorly with the RS. The ability of any of these variables, either alone or in combination, to predict the RS was limited. Similarly, neither commonly used guidelines nor the Adjuvant! Online software were found to be able to predict the RS. CONCLUSIONS. The results of the current study suggest that neither standard clinicopathologic features nor commonly used assessment tools can reliably predict the RS among referred breast cancer patients compared with a clinical trial population. These data also may indicate the need for additional studies regarding the role of the RS among certain subsets of breast cancer patients, including those with noninfiltrating ductal carcinoma histology and the presence of lymph node micrometastasis.

AB - BACKGROUND. The 21-gene recurrence score (RS) assay has been reported to accurately predict the risk of disease recurrence and chemotherapy benefit in women with estrogen receptor (ER)-positive, lymph node (LN)-negative breast cancer who are treated with tamoxifen. To the authors' knowledge, the association between the RS and clinicopathologic characteristics has been studied in randomized and case-control trials, but not in the general population. METHODS. The authors analyzed the correlation between clinicopathologic breast cancer characteristics and RS among 300 consecutive Israeli patients who were referred to undergo the test between October 2004 and October 2006. RESULTS. Low, intermediate, and high RS were noted in 109 patients (36%), 134 patients (45%), and 57 patients (19%), respectively. The median age of the patients was 54 years and the median tumor size was 1.6 cm. High tumor grade, low progesterone receptor expression, infiltrating ductal histology, and high HER-2 expression were found to be associated with a high RS, whereas patient age, tumor size, ER expression, and lymph node micrometastasis were found to correlate poorly with the RS. The ability of any of these variables, either alone or in combination, to predict the RS was limited. Similarly, neither commonly used guidelines nor the Adjuvant! Online software were found to be able to predict the RS. CONCLUSIONS. The results of the current study suggest that neither standard clinicopathologic features nor commonly used assessment tools can reliably predict the RS among referred breast cancer patients compared with a clinical trial population. These data also may indicate the need for additional studies regarding the role of the RS among certain subsets of breast cancer patients, including those with noninfiltrating ductal carcinoma histology and the presence of lymph node micrometastasis.

KW - Breast cancer

KW - Estrogen receptor

KW - Grade

KW - Progesterone receptor

KW - Recurrence score

UR - http://www.scopus.com/inward/record.url?scp=39049103555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049103555&partnerID=8YFLogxK

U2 - 10.1002/cncr.23225

DO - 10.1002/cncr.23225

M3 - Article

C2 - 18076012

AN - SCOPUS:39049103555

VL - 112

SP - 731

EP - 736

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -